Skip to content
My WebMD Sign In, Sign Up

Brain Cancer Health Center

Medical Reference Related to Brain Cancer

  1. Treatment of Recurrent Childhood High-Grade Astrocytomas

    Most patients with high-grade astrocytomas or gliomas will eventually have tumor recurrence, usually within 3 years of original diagnosis but perhaps many years after initial treatment. Disease may recur at the primary tumor site, at the margin of the resection/radiation bed, or at noncontiguous central nervous system sites. Systemic relapse is rare but may occur. At the time of recurrence, a complete evaluation for extent of relapse is indicated for all malignant tumors. Biopsy or surgical resection may be necessary for confirmation of relapse because other entities, such as secondary tumor and treatment-related brain necrosis, may be clinically indistinguishable from tumor recurrence. The need for surgical intervention must be individualized on the basis of the initial tumor type, the length of time between initial treatment and the reappearance of the mass lesion, and the clinical picture. Patients for whom initial treatment fails may benefit from additional treatment.[1]

  2. Questions or Comments About This Summary

    If you have questions or comments about this summary,please send them to Cancer.gov through the Web site’s Contact Form. We can respond only to email messages written in English. ...

  3. Changes to this Summary (04 / 02 / 2013)

    The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.General InformationAdded Mazloom et al. as reference 46.Treatment of Childhood Low-Grade AstrocytomasAdded text about the results of a randomized phase III trial (COG-A9952) that treated children younger than 10 years with low-grade chiasmatic/hypothalamic gliomas using one of two regimens: carboplatin and vincristine (CV) or TPCV; the 5-year event-free survival rate for CV was 39% ± 4% and for TPCV was 52% ± 5%.This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About

  4. Treatment Option Overview

    Many of the improvements in survival in childhood cancer have been made as a result of clinical trials that have attempted to improve on the best available,accepted therapy. Clinical trials in pediatrics are designed to compare new therapy with therapy that is currently accepted as standard. This comparison may be done in a randomized study of two treatment arms or by evaluating a single new ...

  5. Get More Information From NCI

    This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about Neuroblastoma Screening.

  6. About PDQ

    PDQ IS A COMPREHENSIVE CANCER DATABASE AVAILABLE ON NCI'S WEB SITE. PDQ is the National Cancer Institute's (NCI's) comprehensive cancer information database. Most of the information contained in PDQ is available online at NCI's Web site. PDQ is provided as a service of the NCI. The NCI is part of the National Institutes of Health,the federal government's focal point for biomedical research. .

  7. General Information

    This PDQ summary contains content that is also included in the PDQ Childhood Cerebellar Astrocytoma,PDQ Childhood Cerebral Astrocytoma,and PDQ Childhood Visual Pathway/ Hypothalamic Glioma summaries. In the future,the PDQ Childhood Cerebellar Astrocytoma,PDQ Childhood Cerebral Astrocytoma,and PDQ Childhood Visual Pathway/Hypothalamic Glioma summaries.will be removed from the National Cancer ...

  8. About This PDQ Summary

    PURPOSE OF THIS SUMMARY This PDQ cancer information summary for health professionals provides comprehensive,peer-reviewed,evidence-based information about neuroblastoma screening. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions. REVIEWERS AND UPDATES This ...

  9. Spinocerebellar Ataxia with Axonal Neuropathy

    SCAN1 is a neurodegenerative disorder that is inherited in an autosomal recessive pattern. Spinocerebellar ataxia with axonal neuropathy (SCAN1) is characterized by late childhood-onset of a slowly progressive cerebellar ataxia,followed by areflexia and signs of peripheral neuropathy. Gaze nystagmus and cerebellar dysarthria usually develop after the onset of ataxic gait. As the disease ...

  10. Changes to This Summary (02 / 01 / 2013)

    The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above. Editorial changes were made and images were added to this summary.

Displaying 121 - 130 of 226 Articles << Prev Page 9 10 11 12 13 14 15 16 17 18 Next >>

Today on WebMD

human brain xray
Article
Computed Tomography CT Scan Of The Head
Article
 
Integrative Medicine Cancer Quiz
Article
what is your cancer risk
Health Check
 

Malignant Gliomas
Article
Pets Improve Your Health
SLIDESHOW
 
Headache Emergencies
Video
life after a brain tumor
VIDEO
 

Would you consider trying alternative or complementary therapies?


WebMD Special Sections